Ionis Notches Phase III Win in Rare Genetic Disease, Plans to Submit NDA

Topline data from the Phase III Balance study showed that Ionis Pharmaceuticals’ antisense candidate olezarsen met its primary endpoint, significantly reducing triglyceride levels in patients with familial chylomicronemia syndrome, the company announced Tuesday.